Strategies of mucosal immunotherapy for allergic diseases

被引:0
作者
Yi-Ling Ye
Ya-Hui Chuang
Bor-Luen Chiang
机构
[1] National Formosa University,Department of Biotechnology
[2] National Taiwan University,Department of Clinical Laboratory Sciences and Medical Biotechnology
[3] Graduate Institute of Clinical Medicine,undefined
[4] National Taiwan University,undefined
来源
Cellular & Molecular Immunology | 2011年 / 8卷
关键词
adjuvant; allergic disease; mucosal immunotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
Incidences of allergic disease have recently increased worldwide. Allergen-specific immunotherapy (SIT) has long been a controversial treatment for allergic diseases. Although beneficial effects on clinically relevant outcomes have been demonstrated in clinical trials by subcutaneous immunotherapy (SCIT), there remains a risk of severe and sometimes fatal anaphylaxis. Mucosal immunotherapy is one advantageous choice because of its non-injection routes of administration and lower side-effect profile. This study reviews recent progress in mucosal immunotherapy for allergic diseases. Administration routes, antigen quality and quantity, and adjuvants used are major considerations in this field. Also, direct uses of unique probiotics, or specific cytokines, have been discussed. Furthermore, some researchers have reported new therapeutic ideas that combine two or more strategies. The most important strategy for development of mucosal therapies for allergic diseases is the improvement of antigen formulation, which includes continuous searching for efficient adjuvants, collecting more information about dominant T-cell epitopes of allergens, and having the proper combination of each. In clinics, when compared to other mucosal routes, sublingual immunotherapy (SLIT) is a preferred choice for therapeutic administration, although local and systemic side effects have been reported. Additionally, not every allergen has the same beneficial effect. Further studies are needed to determine the benefits of mucosal immunotherapy for different allergic diseases after comparison of the different administration routes in children and adults. Data collected from large, well-designed, double-blind, placebo-controlled, and randomized trials, with post-treatment follow-up, can provide robust substantiation of current evidence.
引用
收藏
页码:453 / 461
页数:8
相关论文
共 725 条
[1]  
Bloomfield SF(2006)Too clean, or not too clean: the hygiene hypothesis and home hygiene Clin Exp Allergy 36 402-425
[2]  
Stanwell-Smith R(1999)Mechanisms of nose-lung interaction Allergy 54 94-105
[3]  
Crevel RW(2000)United airways disease: therapeutic aspects Thorax 55 S26-S27
[4]  
Pickup J(2001)The nose–lung interaction in allergic rhinitis and asthma: united airways disease Curr Opin Allergy Clin Immunol 1 7-13
[5]  
Togias A(2008)Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA Allergy 63 8-160
[6]  
Passalacqua G(2002)LEN and AllerGen) Allergy 57 1048-1052
[7]  
Ciprandi G(2011)The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study Allergy Asthma Immunol Res 3 67-73
[8]  
Canonica GW(2006)The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma J Allergy Clin Immunol 118 152-169
[9]  
Passalacqua G(2011)Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report Proc Am Thorac Soc 8 121-131
[10]  
Ciprandi G(2009)Overview of the treatment of allergic rhinitis and nonallergic rhinopathy Eur J Clin Pharmacol 65 853-871